TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32833285
Drug: Both AST
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both AST and PMH therapies
Study: 34058023
Drug: Plasma transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma transfusion (10–15 cc/kg)
Study: 32933625
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of recombinant human interferon α1b in addition to intravenous drip of acyclovir (observation group)
Study: 32933625
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of acyclovir (control group)
Study: 34635191
Drug: Dissonance‐based body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissonance‐based body project treatment (BPT)
Study: 32510158
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch type 3 (RS‐WM; 22 or 26 g/d for females and males, respectively)
Study: 32236818
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa 500 mg once daily
Study: 33878556
Drug: Probiotic capsule
Normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsule (PC; n = 25) containing probiotic strains
Study: 33878556
Drug: Control capsule
Normalized name: Azo Men Bladder Control Capsules(obs)
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control capsule (CC; n = 20) containing a matching placebo
Study: 35555136
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (300 mg/70 mL) consumed acutely and for 7 days
Study: 35599917
Drug: 30 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg.kg‐1 carnosine and anserine ingestion 60 minutes before performance (Study A)
Study: 35599917
Drug: 30 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg.kg‐1 carnosine and anserine (Study B)
Study: 35599917
Drug: 30 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg.kg‐1 carnosine and anserine, placebo, or antihistamines (Study C)
Study: 32478660
Drug: mHealth app
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth app prescription intervention
Study: 34690120
Drug: Combined tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined tDCS (1.5 mA, 20 min, 12 sessions) + Mindfulness-based substance abuse treatment (MBSAT)
Study: 34690120
Drug: Mindfulness-based substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based substance abuse treatment (MBSAT)
Study: 35634610
Drug: Group-A: Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-A: Capsule Amoxicillin 1 gm; Tablet Clarithromycin 500 mg; Capsule Omeprazole 20 mg, twice daily for two weeks.
Study: 35634610
Drug: Group-B: Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-B: Capsule Amoxicillin 1 gm; Tablet Vonoprazan 20 mg, twice daily for two weeks.
Study: 35971757
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both framing strategies
Study: 35908558
Drug: chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy alone (pemetrexed and cisplatin)
Study: 34033804
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron 1,000 mg
Study: 33992228
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration training (35 Hz) twice a week for 12 weeks
Study: 33617953
Drug: No targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: No targeted therapy (Control)
Study: 33000490
Drug: Neoadjuvant pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pyrotinib in combination with epirubicin and cyclophosphamide followed by docetaxel and trastuzumab (P + EC-TH)
Study: 33290317
Drug: Measures of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measures of interference with activities of daily living
Study: 33735590
Drug: 60 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 μg HB vaccine
Study: 34120835
Drug: Inulin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (10 g/d for females; 15 g/d for males)
Study: 34120835
Drug: Maltodextrin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (6 g/d for females; 9 g/d for males)
Study: 32682668
Drug: Sufentanil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (5 mcg bolus 1 minute before larger dose)
Study: 32682668
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (equal volume 1 minute before larger dose)
Study: 32402773
Drug: Ice cube
Normalized name: N'ICE Cubes 8 MG Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice cube absorption (group 2)
Study: 32402773
Drug: Ice cube
Normalized name: N'ICE Cubes 8 MG Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice cube absorption along with cold vapor application (group 3)
Study: 34911609
Drug: Family rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family rehabilitation treatment performed by parents under the guidance of professionals
Study: 34559118
Drug: EZJDR (Erzhu
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZJDR (Erzhu Jiedu Recipe) administered twice a day after meals for 48 weeks
Study: 35194433
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg sublingual twice daily, then 9 mg single dose 30 min before apheresis session and then 3 mg twice daily from +1 until engraftment)
Study: 36171519
Drug: 23.4% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23.4% NaCl intravenous push
Study: 33507958
Drug: High-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroid pulse therapy (HDCPT) using at least 1.5mg/kg/24h of methylprednisolone or dexamethasone equivalent
Study: 32780797
Drug: Osteopathic Manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Manipulative Treatment (OMT), n=16
Study: 35142586
Drug: Online Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Vaccine Education Program (VEP) videos
Study: 35142586
Drug: Science-based video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Science-based video unrelated to vaccines
Study: 33099032
Drug: Teriparatide (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (human parathyroid hormone 1–34) for 18 months
Study: 35818141
Drug: Timothy grass
Normalized name: Timothy grass
DrugBank: Phleum pratense top (DB14179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timothy grass SLIT-tablet
Study: 33039291
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (IgPro20) 0.2 g/kg bodyweight
Study: 33039291
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (IgPro20) 0.4 g/kg bodyweight
Study: 35422766
Drug: 60 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g/d of whey protein hydrolysate
Study: 35422766
Drug: Maltodextrin with
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin with high (30 g/d) or low (10 g/d) dietary fiber intake
Study: 33899634
Drug: Marketed vaginal
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed vaginal gel (Metron®)
Study: 34789067
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing integrated with Cognitive Behavioral Therapy (MI-CBT)
Study: 34789067
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy alone (CBT-alone)
Study: 36307514
Drug: Combustible cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combustible cigarettes (CC)
Study: 35274710
Drug: SOC +
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOC + IO (mFOLFOX6 + Bevacizumab + Avelumab + CEA-targeted vaccine)
Study: 33799307
Drug: Novel oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel oral nutritional supplement (whey and casein protein, ursolic acid, free branch‐chained amino acids, vitamin D) for 12 weeks
Study: 33799307
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral nutritional supplement for 12 weeks
Study: 34429364
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg rhTNK-tPA (to a maximum of 40 mg)
Study: 34429364
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg rhTNK-tPA (to a maximum of 40 mg)
Study: 34429364
Drug: 0.32 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.32 mg/kg rhTNK-tPA (to a maximum of 40 mg)
Study: 34429364
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg rt-PA (to a maximum of 90 mg)
Study: 34254658
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg intrathecal meperidine
Study: 34254658
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intrathecal meperidine
Study: 34254658
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg intrathecal meperidine
Study: 34254658
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg intrathecal meperidine
Study: 33383570
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate diet (MAX = 10 g/kg body mass CHO daily)
Study: 33383570
Drug: Moderate carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate carbohydrate control diet (CON = 6 g/kg body mass CHO daily)
Study: 35325871
Drug: Argentine tango
Normalized name: Argentine canola pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argentine tango dance intervention (90 minutes, twice a week for 12 weeks)
Study: 33822469
Drug: SAR425899 (0.12,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR425899 (0.12, 0.16 or 0.20 mg)
Study: 33822469
Drug: liraglutide (1.80
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide (1.80 mg)
Study: 34374425
Drug: WRSS1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WRSS1 vaccine (3 doses of 3 × 106 CFU)
Study: 34374425
Drug: WRSS1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WRSS1 vaccine (3 doses of 3 × 105 CFU)
Study: 34374425
Drug: WRSS1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WRSS1 vaccine
Study: 36451722
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg) added to 10 mg hyperbaric bupivacaine 0.5% with 5 µg sufentanil
Study: 36451722
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 10 mg hyperbaric bupivacaine 0.5% with 5 µg sufentanil and 2 ml normal saline
Study: 35279142
Drug: Daily supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supportive text messages (Text4Support) and mental health peer support
Study: 35279142
Drug: Daily supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supportive text messages (Text4Support)
Study: 35838507
Drug: Biofeedback (BF)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biofeedback (BF) and Manual Therapy (MT) with Postural Exercises (PE)
Study: 35838507
Drug: Biofeedback (BF)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biofeedback (BF) and Manual Therapy (MT) with Transcutaneous Electrical Nerve Stimulation (TENS)
Study: 34726808
Drug: NB-OMP (NB-UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB-OMP (NB-UVB and dexamethasone oral mini-pulse therapy)
Study: 34348954
Drug: Recovery-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery-focused therapy (RfT) for older adults with BD; specific dosage and duration not mentioned.
Study: 34215025
Drug: Efpeglenatide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide (4 or 6 mg weekly subcutaneous injections)
Study: 35120127
Drug: CC-11050 (PDE4i)
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-11050 (PDE4i)
Study: 35120127
Drug: auranofin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: auranofin (oral gold salt)
Study: 33588908
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase administration (IVT) at a dosage of 0.9 mg/kg followed by endovascular treatment (EVT)
Study: 33588908
Drug: Direct endovascular
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct endovascular treatment (EVT)
Study: 33588908
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase administration (IVT) followed by EVT
Study: 34129389
Drug: Aerosol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol therapy (specific medications not detailed)
Study: 34129389
Drug: Mucus-regulating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucus-regulating agents
Study: 34129389
Drug: Aerosol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol therapy (general)
Study: 34171967
Drug: Group-based psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based psychosocial intervention with weekly sessions for up to four weeks.
Study: 35805451
Drug: Clinical Pilates
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical Pilates exercises combined with conventional physical therapy (CPT)
Study: 35959221
Drug: Hysteroscopic cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopic cold broad sword play + drospirenone and ethinylestradiol tablets
Study: 35959221
Drug: Hysteroscopic cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopic cold broad sword play + estrogen and progestin sequential therapy
Study: 34225318
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Auditory and Audiovisual Training (AT/AVT)
Study: 39531231
Drug: Brief Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Cognitive Behavioral Therapy (BCBT)
Study: 35986197
Drug: FDC (aripiprazole/divalproex
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC (aripiprazole/divalproex sodium 5/500 mg)
Study: 36070132
Drug: TPIP 112.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPIP 112.5 µg (n=6)
Study: 36070132
Drug: TPIP 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPIP 225 µg QD for 7 days (n=6)
Study: 36070132
Drug: TPIP 112.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPIP 112.5 µg QD for 4 days followed by 225 µg QD for 3 days (n=6)
Study: 36070132
Drug: Placebo (n=2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (n=2 for single-dose, n=4 for multiple-dose)
Study: 32454191
Drug: Intensity Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulated Radiation Therapy with Deep Inspiration Breath Hold (IMRT-DIBH)
Study: 36471430
Drug: Traditional maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional maintenance ICS treatment and symptom-driven SABA
Study: 33300950
Drug: Capecitabine (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (650 mg/m2 twice a day for 1 year)
Study: 35538396
Drug: Point-of-care (PoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care (PoC) HCV RNA testing and direct-acting antiviral (DAA) treatment
Study: 32349879
Drug: Ceftazidime/Avibactam (CAZ-AVI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime/Avibactam (CAZ-AVI) followed by colistin + high-dose meropenem
Study: 32349879
Drug: Meropenem followed
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem followed by colistin + high-dose meropenem
Study: 33527721
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d Alpha Lipoic Acid (ALA)
Study: 33257420
Drug: Non-use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-use of Metformin
Study: 36133316
Drug: Initial L‐T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial L‐T4 dose of 10‐12.5 μg/kg/day (Low)
Study: 36133316
Drug: Initial L‐T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial L‐T4 dose of 12.6‐15 μg/kg/day (High)
Study: 36133316
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment schemes (Low and High)
Study: 33624275
Drug: Intravenous Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tranexamic Acid (TXA) administered as 1 gram bolus and 1 gram every 6 hours for 48 hours
Study: 33624275
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in the same way as TXA
Study: 35180779
Drug: Behavioral sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral sleep treatment
Study: 35180779
Drug: Treatment-as-usual attention-controlled
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual attention-controlled comparison group
Study: 33691506
Drug: Daily steps
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily steps at 2 months poststroke (≥1632 daily steps)
Study: 33691506
Drug: Daily steps
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily steps at 2 months and balance (Berg Balance Scale score)
Study: 33660924
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg/day)
Study: 35322393
Drug: Vibrating insole
Normalized name: VIBRATING DEVICE,CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibrating insole device (VS) with 22-min daily vibrating sequences at 90% of tactile threshold
Study: 38502056
Drug: Mirabegron (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (200 mg)
Study: 34363761
Drug: GARD (genomic-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: GARD (genomic-adjusted radiation dose)
Study: 34363761
Drug: Physical dose
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical dose of radiation
Study: 34363761
Drug: Sham-GARD (standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-GARD (standard-of-care dose without radiotherapy)
Study: 33371043
Drug: 9-month all-oral
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-month all-oral bedaquiline-containing regimen
Study: 34847610
Drug: Lu AG06466
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AG06466 (40 mg)
Study: 35960174
Drug: Standard technique/lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard technique/lidocaine injection
Study: 35960174
Drug: New device/lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: New device/lidocaine patch
Study: 35960174
Drug: New device/lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: New device/lidocaine injection
Study: 33663566
Drug: Tight Control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight Control of psoriatic arthritis (TICOPA) trial with a treat to target (T2T) strategy consisting of 4-weekly review and escalation of therapy (single DMARD, combination DMARDs, and then biologics) based on remission criteria.
Study: 33663566
Drug: T2T approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: T2T approach supported when monitoring treatment within the cohort.
Study: 34978231
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy (DBT) intervention for 10 sessions
Study: 33317579
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal therapy (HFNT)
Study: 32596788
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of ecological executive skills training (EEST)
Study: 32035706
Drug: HUU/3+1 (3-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HUU/3+1 (3-dose priming and booster), HUU/3+0 (3-dose priming without booster), HUU/2+1 (2-dose priming and booster).
Study: 34057299
Drug: Fractionated weekly
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated weekly DCF (D 40 mg/m2, C 35 mg/m², F 1800 mg/m² over 24 h, on days 1 and 8 every 3 weeks)
Study: 34057299
Drug: Fortnightly DCF
Normalized name: TRACH TUBE,SZ 4 CUFFLESS SHLY #4-DCFS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortnightly DCF (D 50 mg/m2, C 50 mg/m², F 2000 mg/m² over 48 h every 2 weeks)
Study: 35779610
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids (INCS) for 3 months
Study: 35779610
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids (INCS) for 12 months
Study: 35015210
Drug: Ulipristal 10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulipristal 10-mg daily
Study: 35015210
Drug: Combination oral
Normalized name: PROBIOTIC COMBINATION ORAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oral contraceptive (COC)
Study: 35106694
Drug: D‐IUI and
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐IUI and D‐IVF treatments in single women (SW)
Study: 35106694
Drug: D‐IUI and
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐IUI and D‐IVF treatments in women in lesbian relationships (WLR)
Study: 35106694
Drug: D‐IUI treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐IUI treatments
Study: 35106694
Drug: D‐IVF treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐IVF treatments